Pancreatic Cancer Research

ResearcherNational Institutes of HealthActive in the last 2 years

Oscar Joe Hines

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-0517-781X; OpenAlex author ID A5047089607; NIH RePORTER profile ID 8585722. Sources: OpenAlex.

Their work

Papers
49 (first author 10, last author 8)
Trials
0
Grants
1
Labs led
1
Collaborators
111
Papers, trials and grants by year

2011: 7 papers, 1 grant · 2012: 3 papers · 2013: 5 papers · 2014: 1 paper · 2015: 5 papers · 2016: 4 papers · 2017: 2 papers · 2018: 7 papers · 2019: 3 papers · 2020: 2 papers · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 3 papers

Papers 49

  1. Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: a propensity s… Co-author DOI 10.1016/j.gassur.2026.102358↗
  2. Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial. Co-author DOI 10.1038/s41467-026-68976-2↗
  3. Prevention Before Therapy in Pancreatic Ductal Adenocarcinoma: The Clinical, Economic, and Human Case for Weighting Resources Upstream. First author DOI 10.1158/1940-6207.capr-26-0197↗
  4. Stress and Obesity Signaling Converge on CREB Phosphorylation to Promote Pancreatic Cancer. Co-author DOI 10.1158/1541-7786.mcr-24-0785↗
  5. Calling Out Disparities in Pancreatic Cancer Care. First author DOI 10.1001/jamasurg.2022.6720↗
  6. Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development in male KrasG12D mice. Co-author DOI 10.1038/s41598-023-43498-9↗
  7. Pathological treatment response has different prognostic implications for pancreatic cancer patients treated with neoadjuvant chemotherapy or chemoradiotherapy. Co-author DOI 10.1016/j.surg.2021.10.015↗
  8. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients. Co-author DOI 10.1002/jso.26279↗
  9. Direct Effects of Lipopolysaccharide on Human Pancreatic Cancer Cells. Co-author DOI 10.1097/mpa.0000000000001790↗
  10. The Effect of Perioperative Blood Transfusion on Long-Term Survival Outcomes After Surgery for Pancreatic Ductal Adenocarcinoma: A Systematic Review. Last author DOI 10.1097/mpa.0000000000001825↗
  11. Should All Patients With Pancreatic Cancer Receive Chemotherapy Before Surgery? First author DOI 10.1001/jamasurg.2020.2302↗
  12. The Utility of EUS-FNA to Determine Surgical Candidacy in Patients with Pancreatic Cancer after Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-019-04415-6↗
  13. Neoadjuvant Therapy of Pancreatic Ductal Adenocarcinoma With Vascular Involvement Shows Promise. First author DOI 10.1001/jamasurg.2019.2278↗
  14. Aggregating Pancreatic Cancer Care to Specialized Centers-A High-Value Decision? First author DOI 10.1001/jamasurg.2019.3020↗
  15. Emerging Evidence for the Clinical Relevance of Pancreatic Cancer Exosomes. First author DOI 10.1097/mpa.0000000000001203↗
  16. The New American Joint Committee on Cancer TNM Staging System for Pancreatic Cancer-Balancing Usefulness With Prognostication. First author DOI 10.1001/jamasurg.2018.3629↗
  17. Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retro… Last author DOI 10.1007/s11523-018-0572-3↗
  18. A Comprehensive Assessment of Accurate Lymph Node Staging and Preoperative Detection in Resected Pancreatic Cancer. Co-author DOI 10.1007/s11605-017-3607-7↗
  19. Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model. Co-author DOI 10.1038/s41598-018-24337-8↗
  20. Obesity and Pancreatic Cancer: Overview of Epidemiology and Potential Prevention by Weight Loss. Co-author DOI 10.1097/mpa.0000000000000974↗
  21. Quality of Life in Patients With Pancreatic Cancer and Their Caregivers: A Systematic Review. Co-author DOI 10.1097/mpa.0000000000001025↗
  22. Deficiency in hormone-sensitive lipase accelerates the development of pancreatic cancer in conditional KrasG12D mice. Co-author DOI 10.1186/s12885-018-4713-y↗
  23. Direct growth-inhibitory effects of prostaglandin E2 in pancreatic cancer cells in vitro through an EP4/PKA-mediated mechanism. Co-author DOI 10.1016/j.surg.2016.12.037↗
  24. Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice. Co-author DOI 10.1371/journal.pone.0184455↗
  25. CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer. Co-author DOI 10.1007/s11605-016-3149-4↗
  26. Long-term survival in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.surg.2015.12.024↗
  27. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. Co-author DOI 10.1038/bjc.2016.121↗
  28. Robust Early Inflammation of the Peripancreatic Visceral Adipose Tissue During Diet-Induced Obesity in the KrasG12D Model of Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000497↗
  29. Long-term Survival After Pancreatic Cancer: Hope Has Arrived. First author DOI 10.1001/jamasurg.2015.0702↗
  30. Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with node-negative disease. Co-author DOI 10.1002/jso.24011↗
  31. E-cadherin expression in obesity-associated, Kras-initiated pancreatic ductal adenocarcinoma in mice. Co-author DOI 10.1016/j.surg.2015.07.023↗
  32. Endoscopic and operative palliation strategies for pancreatic ductal adenocarcinoma. First author DOI 10.1053/j.seminoncol.2014.12.014↗
  33. Early detection of sporadic pancreatic cancer: summative review. Co-author DOI 10.1097/mpa.0000000000000368↗
  34. Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival. Co-author DOI 10.1001/jamasurg.2013.2690↗
  35. Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells. Co-author DOI 10.1016/j.bbamcr.2013.08.006↗
  36. miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells. Co-author DOI 10.1016/j.bbrc.2013.08.042↗
  37. The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. Last author DOI 10.1097/mpa.0b013e318264ccae↗
  38. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system. Co-author DOI 10.1245/s10434-013-3159-3↗
  39. CXCR2: a target for pancreatic cancer treatment? Last author DOI 10.1517/14728222.2013.772137↗
  40. Evidence for activation of mutated p53 by apigenin in human pancreatic cancer. Last author DOI 10.1016/j.bbamcr.2011.12.008↗
  41. Apigenin inhibits NNK-induced focal adhesion kinase activation in pancreatic cancer cells. Co-author DOI 10.1097/mpa.0b013e31824d64d9↗
  42. OA04.02. Mechanisms of growth inhibition of pancreatic cancer by omega-3 polyunsaturated fatty acids Co-author DOI 10.1186/1472-6882-12-s1-o14↗
  43. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Last author DOI 10.1016/j.ajpath.2010.11.058↗
  44. Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. Co-author DOI 10.1016/j.bbamcr.2011.05.003↗
  45. N-myc downstream regulated gene-1 expression correlates with reduced pancreatic cancer growth and increased apoptosis in vitro and in vivo. Co-author DOI 10.1016/j.surg.2010.11.002↗
  46. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Last author DOI 10.1016/j.surg.2011.07.006↗
  47. Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells. Co-author DOI 10.1097/mpa.0b013e31820b9733↗
  48. CXCR2-Dependent Endothelial Progenitor Cell Mobilization in Pancreatic Cancer Growth. Co-author DOI 10.1593/tlo.10184↗
  49. Anti-angiogenic agents in pancreatic cancer: a review. First author DOI 10.2174/187152011795677463↗

Grants 1

  1. UCLA Center for Excellence in Pancreatic Diseases P01AT003960↗

Closest collaborators

The 25 strongest of 111 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guido Eibl · 25 shared papers, 2011–2026 · strength 2.16
  2. Timothy R. Donahue · 13 shared papers, 2013–2026 · strength 1.24
  3. Enrique Rozengurt · 7 shared papers, 2017–2026 · strength 1.23
  4. Jonathan C. King · 10 shared papers, 2011–2026 · strength 0.92
  5. Howard A. Reber · 19 shared papers, 2011–2021 · strength 0.88
  6. Zev A. Wainberg · 8 shared papers, 2013–2026 · strength 0.87
  7. David W. Dawson · 12 shared papers, 2011–2026 · strength 0.82
  8. Mark D. Girgis · 6 shared papers, 2016–2026 · strength 0.80
  9. Linda Ye · 4 shared papers, 2020–2023 · strength 0.75
  10. James W. Sinnett‐Smith · 6 shared papers, 2017–2025 · strength 0.73
  11. Roxanne L. Massoumi · 4 shared papers, 2019–2021 · strength 0.69
  12. Michael A. Mederos · 3 shared papers, 2021–2023 · strength 0.63
  13. Yaroslav Teper · 3 shared papers, 2021–2025 · strength 0.59
  14. Xiaoying Sun · 2 shared papers, 2023–2025 · strength 0.45
  15. Jason M. Link · 2 shared papers, 2026 · strength 0.44
  16. Hui-Hua Chang · 7 shared papers, 2013–2018 · strength 0.42
  17. Vay Liang W. Go · 7 shared papers, 1 shared grant, 2011–2017 · strength 0.35
  18. Shimpei Maeda · 2 shared papers, 2022–2026 · strength 0.34
  19. Mu Xu · 4 shared papers, 2015–2018 · strength 0.34
  20. Motaz Qadan · 2 shared papers, 2022–2026 · strength 0.34
  21. Keith D. Lillemoe · 2 shared papers, 2022–2026 · strength 0.34
  22. V. Raman Muthusamy · 5 shared papers, 2015–2020 · strength 0.34
  23. Alexander P. Stark · 4 shared papers, 2015–2016 · strength 0.27
  24. Stephen Jacob Pandol · 3 shared papers, 2012–2023 · strength 0.26
  25. Joon Y. Park · 2 shared papers, 2021–2022 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.